fda tirzepatide decision approves new weight-loss drug Zepbound (tirzepatide) tirzepatide court UPDATE [March 7,

Recently, our company's independently developed, fully synthetic semaglutide active pharmaceutical ingredient (DMF No.: 039932) has successfully completed the U.S

Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]

Semaglutide injections are an FDA-approved medication originally developed for type 2 diabetes and now widely used for weight loss

The injections are virtually painless and are typically given in the abdomen, thigh, or upper arm